Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis
Contact Dermatitis · 25.05.2026
DOI: 10.1111/cod.70191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contact Dermatitis, online erschienen am 25.05.2026. Verfasst von Shigeruko Iijima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Hanamizuki Clinic, Ibaraki, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Background
Tapinarof cream 1% is a novel, non‐steroidal topical aryl hydrocarbon receptor‐modulating agent approved for the treatment of plaque psoriasis and atopic dermatitis (AD). There has only been one report of allergic sensitization to tapinarof cream.
Objectives
This study aimed to determine whether tapinarof cream‐induced contact dermatitis represents an allergic or irritant reaction, and to identify the causative allergen in allergic cases. Patients/Methods Nine patients (seven with psoriasis and two with AD) who developed contact dermatitis during treatment with tapinarof cream were included. Patch testing was performed with the cream as is ; tapinarof at concentrations of 1%, 0.3%, and 0.1% in petrolatum; and two additives (propylene glycol 10% aqueous solution and disodium edetate hydrate 1% in petrolatum).
Results
Patch testing with tapinarof cream as is was positive in four patients with psoriasis and both patients with AD. All six patients also showed dose–response relationships with tapinarof, increasing from 0.1% to 1%. The remaining three patients with psoriasis showed negative patch test results to both the cream as is and its individual components.
Conclusions
Tapinarof cream‐induced contact dermatitis may present as either an allergic or irritant reaction. In all six allergic cases, tapinarof was strongly suggested to be the causative allergen.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Dermatology, Hanamizuki Clinic, Ibaraki, Japan.
- Department of Dermatology, Ryugasaki Saiseikai Hospital, Ibaraki, Japan.
- General Incorporated Association SSCI-Net, Nagoya, Japan.
- Fujita Health University, Toyoake, Japan.
- Department of Dermatology and Allergy, Kariya Orthopedic Hospital, Kariya, Japan.
ORCID-Profile: Shigeruko Iijima, Kayoko Matsunaga
Zitieren
APA
Iijima, S., Murayama, K., Takayama, N., & Matsunaga, K. (2026). Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis. Contact Dermatitis. https://doi.org/10.1111/cod.70191
Vancouver
Iijima S, Murayama K, Takayama N, Matsunaga K. Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis. Contact Dermatitis. 2026. doi:10.1111/cod.70191
BibTeX
@article{Iijima2026,
author = {Iijima, Shigeruko and Murayama, Kayo and Takayama, Noriko and Matsunaga, Kayoko},
title = {Tapinarof as a Likely Contact Allergen: Evidence From Patch Testing of Allergic and Irritant Contact Dermatitis},
journal = {Contact Dermatitis},
year = {2026},
doi = {10.1111/cod.70191}
}
EUVIMED